Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Caribou aims to set itself apart from the allogeneic Car-T herd
For now, the group is sticking with what it knows ahead of a big year in lymphoma.
CD47’s long goodbye
Despite magrolimab’s latest flop, efforts to target CD47 continue.
Gilead doubles down on Arcus
Will a TIGIT refocus see the stars finally align for the partners?
